Oropharyngeal Cancer - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Oropharyngeal Cancer - Pipeline Review, H2 2018’, provides an overview of the Oropharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer

- The report reviews pipeline therapeutics for Oropharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Oropharyngeal Cancer therapeutics and enlists all their major and minor projects

- The report assesses Oropharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advaxis Inc

AMI Onco Theranostics LLC

Astex Pharmaceuticals Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

Eisai Co Ltd

GlaxoSmithKline Plc

IMV ...

AbbVie Inc

Advaxis Inc

AMI Onco Theranostics LLC

Astex Pharmaceuticals Inc

AstraZeneca Plc

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

Eisai Co Ltd

GlaxoSmithKline Plc

IMV Inc

Incyte Corp

Innate Pharma SA

IRX Therapeutics Inc

ISA Pharmaceuticals BV

Kite Pharma Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Ono Pharmaceutical Co Ltd

Pfizer Inc

PNP Therapeutics Inc

Regeneron Pharmaceuticals Inc

Shionogi & Co Ltd

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Transgene SA

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Oropharyngeal Cancer – Overview 5

Oropharyngeal Cancer – Therapeutics Development 6

Oropharyngeal Cancer – Therapeutics Assessment 12

Oropharyngeal Cancer ...

Table of Contents

Table of Contents 2

Introduction 4

Oropharyngeal Cancer – Overview 5

Oropharyngeal Cancer – Therapeutics Development 6

Oropharyngeal Cancer – Therapeutics Assessment 12

Oropharyngeal Cancer – Companies Involved in Therapeutics Development 20

Oropharyngeal Cancer – Drug Profiles 33

Oropharyngeal Cancer – Dormant Projects 364

Oropharyngeal Cancer – Discontinued Products 365

Oropharyngeal Cancer – Product Development Milestones 366

Appendix 374

List of Tables

List of Tables

Number of Products under Development for Oropharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Oropharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Oropharyngeal Cancer – Pipeline by AbbVie Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Advaxis Inc, H2 2018

Oropharyngeal Cancer – Pipeline by AMI Onco Theranostics LLC, H2 2018

Oropharyngeal Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2018

Oropharyngeal Cancer – Pipeline by AstraZeneca Plc, H2 2018

Oropharyngeal Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Oropharyngeal Cancer – Pipeline by Celldex Therapeutics Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Eisai Co Ltd, H2 2018

Oropharyngeal Cancer – Pipeline by GlaxoSmithKline Plc, H2 2018

Oropharyngeal Cancer – Pipeline by IMV Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Incyte Corp, H2 2018

Oropharyngeal Cancer – Pipeline by Innate Pharma SA, H2 2018

Oropharyngeal Cancer – Pipeline by IRX Therapeutics Inc, H2 2018

Oropharyngeal Cancer – Pipeline by ISA Pharmaceuticals BV, H2 2018

Oropharyngeal Cancer – Pipeline by Kite Pharma Inc, H2 2018

Oropharyngeal Cancer – Pipeline by MedImmune LLC, H2 2018

Oropharyngeal Cancer – Pipeline by Merck & Co Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Merck KGaA, H2 2018

Oropharyngeal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Oropharyngeal Cancer – Pipeline by Pfizer Inc, H2 2018

Oropharyngeal Cancer – Pipeline by PNP Therapeutics Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Shionogi & Co Ltd, H2 2018

Oropharyngeal Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H2 2018

Oropharyngeal Cancer – Pipeline by Theralase Technologies Inc, H2 2018

Oropharyngeal Cancer – Pipeline by Transgene SA, H2 2018

Oropharyngeal Cancer – Dormant Projects, H2 2018

Oropharyngeal Cancer – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Oropharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Oropharyngeal Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports